Although generally well tolerated compared with chemotherapy, molecular targeted therapy used in metastatic melanoma may be associated with life-threatening toxicity. We report the case of a patient with metastatic melanoma treated by dabrafenib plus trametinib who developed intracranial hemorrhage. Physicians should be aware of this rare but life-threatening adverse event of B-rapidly accelerated fibrosarcoma (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors. However, they should be also careful about the bleeding origin, which can prove to be a new onset of melanoma metastasis or anticoagulation overdose, or even an uncontrolled arterial hypertension.
Keyphrases
- arterial hypertension
- atrial fibrillation
- protein kinase
- optic nerve
- primary care
- tyrosine kinase
- case report
- venous thromboembolism
- oxidative stress
- locally advanced
- pi k akt
- squamous cell carcinoma
- radiation therapy
- metastatic colorectal cancer
- newly diagnosed
- signaling pathway
- optical coherence tomography
- rectal cancer
- basal cell carcinoma